Relmada Therapeutics is a clinical stage, publicly traded biotechnology company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of central nervous system CNS diseases. The Company has a diversified portfolio of four products at various stages of development, including d Methadone dextromethadone, REL , an N methyl D aspartate NMDA receptor antagonist for depression and neuropathic pain LevoCap ER REL , an abuse resistant, sustained release dosage form of the opioid analgesic levorphanol oral buprenorphine BuTab, REL , an oral dosage form of the opioid analgesic buprenorphine and topical mepivacaine MepiGel, REL , an orphan drug designated topical formulation of the local anesthetic mepivacaine. The Company s product development efforts are guided by the internationally recognized scientific expertise of its research team. The Company s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products to address areas of high unmet medical needs.
Quote | Relmada Therapeutics Inc. (OTCMKTS:RLMD)
Last: | $ |
---|---|
Change Percent: | -1.10% |
Open: | $42.00 |
Close: | $41.51 |
High: | $42.475 |
Low: | $41.11 |
Volume: | 45,680 |
Last Trade Date Time: | 02/12/2020 04:57:15 pm |
News | Relmada Therapeutics Inc. (OTCMKTS:RLMD)
Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry PR Newswire CORAL GABLES, Fla. , June 18, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage b...
Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference PR Newswire CORAL GABLES, Fla. , June 10, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of t...
Message Board Posts | Relmada Therapeutics Inc. (OTCMKTS:RLMD)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $RLMD News Article - Relmada Therapeutics Appoints Fabiana Fedeli from M&G Investments | whytestocks | investorshangout | 01/12/2023 3:25:46 PM |
whytestocks: $RLMD News Article - Relmada Therapeutics Appoints CNS Therapeutic Expert Cedric O'Gorm | whytestocks | investorshangout | 01/09/2023 7:50:50 PM |
whytestocks: $RLMD News Article - Relmada Therapeutics Receives FDA Fast Track Designation for REL-1 | whytestocks | investorshangout | 08/09/2022 11:10:57 PM |
whytestocks: $RLMD News Article - Relmada Therapeutics Announces Publication of REL-1017 Preclinical | whytestocks | investorshangout | 04/29/2022 5:15:52 PM |
This stock just wont quit. Love it! | Glider549 | investorshub | 04/03/2022 11:17:19 PM |
News, Short Squeeze, Breakout and More Instantly...
Relmada Therapeutics Inc. Company Name:
RLMD Stock Symbol:
OTCMKTS Market:
Relmada Therapeutics Inc. Website:
Relmada Therapeutics Announced Publication of Results from the Phase 3 Reliance I Study of REL-1017 in The Journal of Clinical Psychiatry PR Newswire CORAL GABLES, Fla. , June 18, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage b...
Relmada Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference PR Newswire CORAL GABLES, Fla. , June 10, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of t...
Relmada Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference PR Newswire CORAL GABLES, Fla. , June 3, 2024 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the cent...